Emerging therapies for AMD management

Video

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Anat Loewenstein, MD, chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

See more AMD Awareness content here, here, and here.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Related Content
An elderly woman undergoes an eye exam. Image credit: ©cherryandbees – stock.adobe.com

I-SCREEN programme will use AI and OCT imaging to identify and monitor AMD

April 17th 2024
Article
The ZEISS Meditec logo in front of a graph showing a line up. Image credit: ©piter2121 – stock.adobe.com

Carl Zeiss Meditec AG announces completed acquisition of Dutch Ophthalmic Research Center

April 4th 2024
Article

Zeiss has secured regulatory approvals to acquire DORC and will shift focus to integration implementation

A detective looks through a magnifying glass at an eyeball. Image created with Canva AI.

Hemorrhagic unilateral retinopathy: No proven aetiology for rare condition

April 2nd 2024
Article

Multimodal imaging and a systemic work-up failed to identify any underlying disorder for the hemorrhages

Glasses with an overlay of digital data outputs on the surface. Image credit: ©Taiwo – stock.adobe.com

Exonate shares results from Phase Ib/IIa trial of EXN407 eye drops for DR and DME

March 27th 2024
Article

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

A hand writes a red check mark into a box on a white background. Image credit: ©Mihail – stock.adobe.com

Outlook Therapeutics receives positive CHMP opinion for bevacizumab for wet age-related macular degeneration

March 22nd 2024
Article

The European Commission is expected to make a decision about the application before the end of June

A scale, evenly balanced, with "risk" on one side and "benefit" on the other. ©Who is Danny – stock.adobe.com

COPHy 2024: Intraocular inflammation as a risk factor resulting from use of anti-complement agents for GA

March 15th 2024
Article

Good news for patients: use of anti-complement therapies have caused the growth rate of GA lesions to decrease

© 2024 MJH Life Sciences

All rights reserved.